504 related articles for article (PubMed ID: 28742702)
1. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
Poodt IGM; Spronk PER; Vugts G; van Dalen T; Peeters MTFDV; Rots ML; Kuijer A; Nieuwenhuijzen GAP; Schipper RJ
Ann Surg; 2018 Dec; 268(6):1084-1090. PubMed ID: 28742702
[TBL] [Abstract][Full Text] [Related]
2. The administration of adjuvant chemo(-immuno) therapy in the post ACOSOG-Z0011 era; a population based study.
Poodt IGM; Rots ML; Vugts G; van Dalen T; Kuijer A; Vriens BEPJ; Nieuwenhuijzen GAP; Schipper RJ
Eur J Surg Oncol; 2018 Aug; 44(8):1151-1156. PubMed ID: 29580733
[TBL] [Abstract][Full Text] [Related]
3. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
4. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
5. A Population-Based Study of the Effects of a Regional Guideline for Completion Axillary Lymph Node Dissection on Axillary Surgery in Patients with Breast Cancer.
Tsao MW; Cornacchi SD; Hodgson N; Simunovic M; Thabane L; Cheng J; O'Brien MA; Strang B; Mukherjee SD; Lovrics PJ
Ann Surg Oncol; 2016 Oct; 23(10):3354-64. PubMed ID: 27342830
[TBL] [Abstract][Full Text] [Related]
6. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
Riedel F; Heil J; Feißt M; Rezai M; Moderow M; Sohn C; Schütz F; Golatta M; Hennigs A
Breast Cancer Res Treat; 2019 Sep; 177(2):457-467. PubMed ID: 31236814
[TBL] [Abstract][Full Text] [Related]
7. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
8. The exportability of the ACOSOG Z0011 criteria for omitting axillary lymph node dissection after positive sentinel lymph node biopsy findings: a multicenter study.
Delpech Y; Bricou A; Lousquy R; Hudry D; Jankowski C; Willecocq C; Thoury A; Loustalot C; Coutant C; Barranger E
Ann Surg Oncol; 2013 Aug; 20(8):2556-61. PubMed ID: 23456432
[TBL] [Abstract][Full Text] [Related]
9. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
Riedel F; Heil J; Feisst M; Moderow M; von Au A; Domschke C; Michel L; Schaefgen B; Golatta M; Hennigs A
Breast Cancer Res Treat; 2020 Nov; 184(2):627-636. PubMed ID: 32816190
[TBL] [Abstract][Full Text] [Related]
10. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
[TBL] [Abstract][Full Text] [Related]
11. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
[TBL] [Abstract][Full Text] [Related]
12. The State of Surgical Axillary Management and Adjuvant Radiotherapy for Early-stage Invasive Breast Cancer in the Modern Era.
Mann JM; Wu X; Christos P; Nagar H
Clin Breast Cancer; 2018 Aug; 18(4):e477-e493. PubMed ID: 29031423
[TBL] [Abstract][Full Text] [Related]
13. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
14. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
Hennigs A; Riedel F; Feißt M; Köpke M; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Heil J
Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
[TBL] [Abstract][Full Text] [Related]
15. Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?
Pilewskie M; Mautner SK; Stempel M; Eaton A; Morrow M
Ann Surg Oncol; 2016 Apr; 23(4):1123-8. PubMed ID: 26553439
[TBL] [Abstract][Full Text] [Related]
16. Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era.
Liang Y; Chen X; Tong Y; Zhan W; Zhu Y; Wu J; Huang O; He J; Zhu L; Li Y; Chen W; Shen K
World J Surg Oncol; 2019 Feb; 17(1):37. PubMed ID: 30786903
[TBL] [Abstract][Full Text] [Related]
17. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.
Barrio AV; Downs-Canner S; Edelweiss M; Van Zee KJ; Cody HS; Gemignani ML; Pilewskie ML; Plitas G; El-Tamer M; Kirstein L; Capko D; Patil S; Morrow M
Ann Surg Oncol; 2020 May; 27(5):1617-1624. PubMed ID: 31820212
[TBL] [Abstract][Full Text] [Related]
18. Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study.
Gannan E; Khoo J; Nightingale S; Suhardja TS; Lippey J; Keane H; Tan KJ; Clouston D; Gorelik A; Mann GB;
Breast J; 2016 Jul; 22(4):413-9. PubMed ID: 27095381
[TBL] [Abstract][Full Text] [Related]
19. Patient Age and Tumor Subtype Predict the Extent of Axillary Surgery Among Breast Cancer Patients Eligible for the American College of Surgeons Oncology Group Trial Z0011.
Ong CT; Thomas SM; Blitzblau RC; Fayanju OM; Park TS; Plichta JK; Rosenberger LH; Hyslop T; Shelley Hwang E; Greenup RA
Ann Surg Oncol; 2017 Nov; 24(12):3559-3566. PubMed ID: 28879416
[TBL] [Abstract][Full Text] [Related]
20. [Positive sentinel node in breast cancer - when and why also opt for axillary dissection?].
Krsička P; Coufal O; Zapletal O
Rozhl Chir; 2013 Dec; 92(12):684-9. PubMed ID: 24479511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
